LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function

Trial Profile

LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Dec 2017 According to a Mesoblast media release, based on the data of this trial, the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for mesenchymal precursor cell (MPC) therapy to treat patients with heart failure with LVSD and LVADs.
    • 20 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top